Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib with Chemotherapy in Relapsed t(8;21) AML with KIT D816 Mutation
NCT03560908Phase 1Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: composite complete remission (CR) rate at 8 weeks. Planned start Jul 2018; status: withdrawn.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03560908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560908.